Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
Saved in:
| Title: | Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial. |
|---|---|
| Authors: | Sehgal K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Pappa T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Shin KY; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Schiantarelli J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Liu M; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Ricker C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Besson NR; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Jones SM; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Welsh EL; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Pfaff KL; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Barletta JA; Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Park J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Reardon B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Doherty GM; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Alexander EK; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Rodig SJ; Harvard Medical School, Boston, Massachusetts.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., O'Neill A; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Van Allen E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Haddad RI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Lorch JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts.; Head and Neck/Thyroid Program, Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois. |
| Source: | JAMA oncology [JAMA Oncol] 2024 Dec 01; Vol. 10 (12), pp. 1663-1671. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
